Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders

article OA: diamond CC0 ⤵ 1 in-corpus citation
AI-generated summary by gemini-2.5-flash-lite, 2026-06-09

This study found serum HE4 levels were less elevated than CA125 in Chinese women with benign gynecologic disorders, suggesting HE4 is a more suitable biomarker.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by qwen3.7-flash, 2026-08-28 · read from full text

The provided text consists entirely of the journal’s open access policy and author license agreement for African Health Sciences, rather than the scientific content of a research article. It outlines the terms under which papers are published, including the Creative Commons Attribution License 4.0, copyright permissions, and requirements for attribution and integrity. The title referencing serum HE4 and CA125 appears to be metadata associated with the submission but is not present in the body text provided. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

OBJECTIVE: This study measured the human epididymis protein 4 (HE4) and CA125 levels in Chinese women with benign gynecological disorders. MATERIAL AND METHODS: Sera were obtained from Chinese women prior to surgery for a pelvic mass and HE4 and CA125 levels were determined. The proportions of patients with HE4 and CA125 levels were compared. RESULTS: There were 68 Chinese women with benign diseases. HE4 levels were less elevated than CA125 (1% V.S. 29%, P<0.001). The significant difference was observed in patients with endometriosis/endometriomas in which HE4 was not elevated patients and CA125 was elevated in 53% (P<0.001). Serum HE4 level was not elevated in patients with cystadenoma (0% V.S. 23%, P<0.001) and in patients with germ cell tumors (0% V.S. 5%, P<0.001). CONCLUSION: HE4 was less elevated and more suitable as a biomarker than CA125 in chinese women with benign disease.
Full text 2,246 characters · extracted from oa-doi-fallback · click to expand
A. AFRICAN HEALTH SCIENCES OPEN ACCESS POLICYWhile African Health Sciences has been freely accessible online there have been questions on whether it is Open Access or not. We wish to clearly state that indeed African Health Sciences is Open Access. There are key issues regarding Open Access needing clarification for avoidance of doubt: - 1. Henceforth, papers in African Health Sciences will be published under the CC BY (Creative Commons Attribution License) 4.0 International. See details on https://creativecomons.org/) - 2. The copyright owners or the authors grant the 3rd party (perpetually and in advance) the right to disseminate, reproduce, or use the research papers in part or in full, format/medium as long as: - No substantive errors are introduced in the process - Attribution of authorship and correct citation details are given - The referencing details are not changed. Should the papers be reproduced in part, this must be clearly stated. - 3. The papers will be freely and universally accessible online in an easily readable format such as XML in at least one widely recognized open access repository such as PUBMED CENTRAL. B. ABRIDGED LICENCE AGREEMENT BETWEEN AUTHORS AND African Health Sciences I submitted my manuscript to African Health Sciences and would like to affirm that: 1.0 I am authorized by my co-authors to enter into these arrangements. 2.0 I guarantee, on behalf of self and co-authors: - That the paper is original, and has not been published in any other peer-reviewed journal; nor is it under consideration by other journal (s). It does not infringe existing copyright or any other person’s rights - That we are/I am the sole author(s) of the paper and with authority to enter into this agreement. My granting rights to African Health Sciences is not in breach of any other obligation - That the paper contains nothing unlawful, or libelous. Nor anything that would constitute a breach of contract, confidence or commitment given to secrecy, if published - That I/we have taken care to ensure the integrity of the article. 3.0 I and all co-authors, agree that the paper, if accepted for publication, shall be licensed under the Creative Commons Attribution License 4.0. (see https://creativecommons.org/)

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Asian People Biomarkers, Tumor CA-125 Antigen Genital Diseases, Female Membrane Proteins Proteins Adult Asian People Biomarkers, Tumor CA-125 Antigen CA-125 Antigen Female Genital Diseases, Female Genital Diseases, Female Genital Diseases, Female Humans Membrane Proteins Membrane Proteins Middle Aged Predictive Value of Tests

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

Cited by (1)

References (33)

Cited by (1)

Source provenance

europepmc
last seen: 2026-09-14T06:17:53.580500+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:17:58.238279+00:00
License: CC0 · commercial use OK